Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Plus Therapeutics Inc

Company price
None USD 0.00(0%)
Last update at 2026-11-20T21:01:34.277681Z
Market Cap
26.64M
P/E
0.18

Momentum Score

…

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.90
Low
23.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Plus Therapeutics Inc develops targeted radiotherapeutics using nanoliposome and radiopharmaceutical technologies for oncology indications with high unmet need. Its long-term growth may be supported by successful clinical trials, regulatory approvals, indication expansion and manufacturing or partner scale-up. The company appears positioned to attract investors interested in niche oncology platforms that could benefit from growing adoption of targeted radiotherapy.
The most important investment risks are clinical and regulatory execution risk, likely ongoing capital requirements and manufacturing complexity that could delay commercialization or cause dilution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
5.18M
Revenue Per Share
1.12
Gross Profit TTM
-4.31M
Debt / Equity
0.21
ROE
-522.50%
Net Debt
-7.94M
ROCE
-468.14%
Diluted EPS TTM
21.56

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -22.39M -12.98M -13.32M -20.27M -13.40M
Net income -22.39M -12.98M -13.32M -20.84M -14.33M
Selling general administrative 12.13M 9.94M 8.54M 10.24M 6.85M
Selling and marketing expenses - - 0.74M - -
Gross profit 4.77M 4.97M -4.78M 0.22M -0.07M
Reconciled depreciation 0.45M 0.72M 0.63M 0.62M 0.40M
Ebit -18.78M -9.25M -12.92M -19.71M -12.49M
Ebitda -18.33M -8.40M -12.29M -18.95M -12.01M
Depreciation and amortization 0.45M 0.85M 0.63M 0.77M 0.48M
Operating income -15.30M -14.70M -13.32M -19.71M -12.49M
Other operating expenses 20.51M 20.52M 18.23M 19.94M 12.43M
Interest expense 3.61M 3.72M 0.40M 0.71M 0.93M
Interest income 0.12M 0.27M 0.40M 0.15M 0.02M
Net interest income -3.49M -3.45M 0.01M -0.56M -0.91M
Income tax expense - - - 0.56M 0.93M
Total revenue 5.21M 5.82M 4.91M 0.22M 0.00M
Total operating expenses 20.07M 19.67M 8.54M 19.94M 12.43M
Cost of revenue 0.45M 0.85M 9.69M - 0.07M
Total other income expense net -7.09M 1.72M 0.01M -0.56M -0.91M
Net income from continuing ops -22.39M -12.98M -13.32M -20.27M -13.40M
Net income applicable to common shares - - - -20.27M -13.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 16.32M 6.63M 11.39M 23.87M 21.98M
Intangible assets 0.33M 0.47M 0.04M 0.09M 0.05M
Other current assets 6.41M 1.08M 1.28M 3.70M 1.32M
Total liab 12.33M 15.58M 12.74M 17.42M 11.14M
Total stockholder equity 4.00M -8.95M -1.35M 6.45M 10.84M
Other current liab 8.23M 2.74M 1.87M 1.77M 0.12M
Common stock 0.14M 0.01M 0.01M 0.03M 0.02M
Capital stock 0.14M 0.01M 0.01M 0.03M 0.02M
Retained earnings -515.87M -493.48M -480.50M -467.19M -446.91M
Other liab - - - 1.64M 0.00M
Good will 0.37M 0.37M 0.37M 0.37M 0.37M
Other assets - - - 0.01M 0.02M
Cash 8.76M 0.08M 8.55M 18.12M 18.40M
Total current liabilities 12.31M 15.55M 10.73M 11.85M 5.87M
Current deferred revenue - - - - 1.42M
Net debt -7.94M 3.29M -4.37M -12.47M -11.41M
Short term debt 0.81M 3.34M 4.10M 1.72M 1.72M
Short long term debt 0.75M 3.29M 3.98M 1.61M 1.61M
Short long term debt total 0.82M 3.37M 4.18M 5.64M 6.99M
Other stockholder equity 519.72M 484.52M 479.15M 473.60M 457.73M
Property plant equipment - - - 1.57M 1.82M
Total current assets 15.17M 5.26M 9.83M 21.82M 19.72M
Net tangible assets - - - 5.98M 10.41M
Short term investments 4.36M 3.53M - - -
Net receivables - 0.57M - - 0.01M
Long term debt - - - 3.79M 5.00M
Inventory - - - - -0.01M
Accounts payable 3.28M 9.47M 4.76M 8.36M 2.61M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.12M 0.01M 0.03M 0.01M 0.02M
Non current assets total 1.16M 1.37M 1.55M 2.05M 2.26M
Capital lease obligations 0.07M 0.07M 0.20M 0.25M 0.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.82M -4.11M -0.16M -0.76M -0.08M
Change to liabilities - - - 6.45M 1.73M
Total cashflows from investing activities -0.85M -4.11M -0.16M -0.76M -0.08M
Net borrowings -2.51M -0.70M -1.61M -1.61M -0.28M
Total cash from financing activities 30.31M 6.19M 3.44M 13.45M 20.42M
Change to operating activities - - - -0.85M -0.50M
Net income -22.39M -12.98M -13.32M -20.27M -13.40M
Change in cash 8.68M -8.48M -9.57M -0.28M 10.05M
Begin period cash flow 0.08M 8.55M 18.12M 18.40M 8.35M
End period cash flow 8.76M 0.08M 8.55M 18.12M 18.40M
Total cash from operating activities -20.77M -10.55M -12.85M -12.97M -10.28M
Issuance of capital stock 38.54M 7.26M 5.53M 15.06M 18.68M
Depreciation 0.45M 0.72M 0.63M 0.62M 0.40M
Other cashflows from investing activities 0.03M -0.55M - - -
Dividends paid - - 0.35M - -
Change to account receivables 0.25M -0.57M - - 0.00M
Sale purchase of stock 0.00M -0.37M -0.13M - -
Other cashflows from financing activities 19.37M -0.70M -0.35M -0.76M 2.02M
Change to netincome - - - 0.60M 0.94M
Capital expenditures 0.07M 0.15M 0.16M 0.51M 0.14M
Change in working capital -6.04M 3.22M -1.12M 5.60M 1.24M
Stock based compensation 1.54M 0.55M 0.57M 0.61M 0.61M
Other non cash items 5.67M -2.07M 0.38M 0.48M 0.82M
Free cash flow -20.84M -10.70M -13.01M -13.48M -10.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021

737 255 7194

28

Name Title Year Born
Dr. Marc H. Hedrick M.D. Pres, CEO & Director 1963
Mr. Andrew J. Sims VP & CFO 1974
Dr. Norman D. LaFrance FACNP, FACP, M.D. Chief Medical Officer & Sr. VP 1948
Ms. Desiree Smith Corp. Controller, Principal Financial & Accounting Officer 1964
Dr. John K. Fraser Chief Scientist 1961
Mr. Russ Havranek M.B.A., M.S. VP of Corp. Strategy, New Product Planning & Investor Relations NA
Mr. Gary S. Titus CPA Advisor 1960
Dr. Marc H. Hedrick M.B.A., M.D. President, CEO & Director 1963
Mr. Andrew J. Sims CPA VP of Finance & CFO 1973
Dr. Norman D. LaFrance FACNP, FACP, M.D. Chief Medical Officer & Senior VP 1948

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…